Compile Data Set for Download or QSAR
maximum 50k data
Found 37 with Last Name = 'reineke' and Initial = 'u'
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466499(US10799605, Example 4)
Affinity DataIC50:  0.870nMAssay Description:In order to determine the binding affinity of compounds comprising a radiolabel for NTR1, a radioligand binding assay was carried out. A radioligand ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466500(US10799605, Example 5)
Affinity DataIC50:  2.90nMAssay Description:In order to determine the binding affinity of compounds comprising a radiolabel for NTR1, a radioligand binding assay was carried out. A radioligand ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466502(US10799605, Example 13)
Affinity DataIC50:  3nMAssay Description:In order to determine the binding affinity of compounds comprising a radiolabel for NTR1, a radioligand binding assay was carried out. A radioligand ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466505(US10799605, Example 19)
Affinity DataIC50:  3.40nMAssay Description:In order to determine the binding affinity of compounds comprising a radiolabel for NTR1, a radioligand binding assay was carried out. A radioligand ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466501(US10799605, Example 12)
Affinity DataIC50:  4.90nMAssay Description:In order to determine the binding affinity of compounds comprising a radiolabel for NTR1, a radioligand binding assay was carried out. A radioligand ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466504(US10799605, Example 18)
Affinity DataIC50:  5.30nMAssay Description:In order to determine the binding affinity of compounds comprising a radiolabel for NTR1, a radioligand binding assay was carried out. A radioligand ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466499(US10799605, Example 4)
Affinity DataIC50:  7.54nMAssay Description:Ca2+ ions are usually kept at nanomolar levels in the cytosol of cells, and act in a number of signal transduction pathways as second messengers. Man...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466504(US10799605, Example 18)
Affinity DataIC50:  8.95nMAssay Description:Ca2+ ions are usually kept at nanomolar levels in the cytosol of cells, and act in a number of signal transduction pathways as second messengers. Man...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466505(US10799605, Example 19)
Affinity DataIC50:  12.6nMAssay Description:Ca2+ ions are usually kept at nanomolar levels in the cytosol of cells, and act in a number of signal transduction pathways as second messengers. Man...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466502(US10799605, Example 13)
Affinity DataIC50:  17.5nMAssay Description:Ca2+ ions are usually kept at nanomolar levels in the cytosol of cells, and act in a number of signal transduction pathways as second messengers. Man...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466500(US10799605, Example 5)
Affinity DataIC50:  20nMAssay Description:Ca2+ ions are usually kept at nanomolar levels in the cytosol of cells, and act in a number of signal transduction pathways as second messengers. Man...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466501(US10799605, Example 12)
Affinity DataIC50:  21.4nMAssay Description:Ca2+ ions are usually kept at nanomolar levels in the cytosol of cells, and act in a number of signal transduction pathways as second messengers. Man...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141994(US8927534, 269)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141990(US8927534, 266)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141986(US8927534, 262)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM50423736(CHEMBL591543)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141981(US8927534, 120)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141973(US8927534, 114 | US8927534, 83)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141979(US8927534, 75)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141978(US8927534, 29)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141976(US8927534, 23)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141975(US8927534, 20)
Affinity DataIC50: >100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM50423721(CHEMBL595105)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141972(US8927534, 11)
Affinity DataIC50: >100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeurotensin receptor type 1(Homo sapiens (Human))
3B Pharmaceuticals

US Patent
LigandPNGBDBM466506(US10799605, Example 22)
Affinity DataIC50:  125nMAssay Description:Ca2+ ions are usually kept at nanomolar levels in the cytosol of cells, and act in a number of signal transduction pathways as second messengers. Man...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141986(US8927534, 262)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM50423736(CHEMBL591543)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141981(US8927534, 120)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141973(US8927534, 114 | US8927534, 83)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141979(US8927534, 75)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141994(US8927534, 269)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141976(US8927534, 23)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141975(US8927534, 20)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141972(US8927534, 11)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM50423721(CHEMBL595105)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141990(US8927534, 266)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141978(US8927534, 29)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent